RT Journal Article
SR Electronic
T1 <sup>90</sup>Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 665
OP 671
DO 10.2967/jnumed.115.166082
VO 57
IS 5
A1 Hickey, Ryan
A1 Lewandowski, Robert J.
A1 Prudhomme, Totianna
A1 Ehrenwald, Eduardo
A1 Baigorri, Brian
A1 Critchfield, Jeffrey
A1 Kallini, Joseph
A1 Gabr, Ahmed
A1 Gorodetski, Boris
A1 Geschwind, Jean-Francois
A1 Abbott, Andrea
A1 Shridhar, Ravi
A1 White, Sarah B.
A1 Rilling, William S.
A1 Boyer, Brendan
A1 Kauffman, Shannon
A1 Kwan, Sharon
A1 Padia, Siddarth A.
A1 Gates, Vanessa L.
A1 Mulcahy, Mary
A1 Kircher, Sheetal
A1 Nimeiri, Halla
A1 Benson, Al B.
A1 Salem, Riad
YR 2016
UL http://jnm.snmjournals.org/content/57/5/665.abstract
AB Hepatic metastases of colorectal carcinoma are a leading cause of cancer-related mortality. Most colorectal liver metastases become refractory to chemotherapy and biologic agents, at which point the median overall survival declines to 4–5 mo. Radioembolization with 90Y has been used in the salvage setting with favorable outcomes. This study reports the survival and safety outcomes of 531 patients treated with glass-based 90Y microspheres at 8 institutions, making it the largest 90Y study for patients with colorectal liver metastases. Methods: Data were retrospectively compiled from 8 institutions for all 90Y glass microsphere treatments for colorectal liver metastases. Exposure to chemotherapeutic or biologic agents, prior liver therapies, biochemical parameters before and after treatment, radiation dosimetry, and complications were recorded. Uni- and multivariate analyses for predictors of survival were performed. Survival outcomes and clinical or biochemical adverse events were recorded. Results: In total, 531 patients received 90Y radioembolization for colorectal liver metastases. The most common clinical adverse events were fatigue (55%), abdominal pain (34%), and nausea (19%). Grade 3 or 4 hyperbilirubinemia occurred in 13% of patients at any time. The median overall survival from the first 90Y treatment was 10.6 mo (95% confidence interval, 8.8–12.4). Performance status, no more than 25% tumor burden, no extrahepatic metastases, albumin greater than 3 g/dL, and receipt of no more than 2 chemotherapeutic agents independently predicted better survival outcomes. Conclusion: This multiinstitutional review of a large cohort of patients with colorectal liver metastases treated with 90Y radioembolization using glass microspheres has demonstrated promising survival outcomes with low toxicity and low side effects. The outcomes were reproducible and consistent with prior reports of radioembolization.